Ritu Salani, MD, MBA, UCLA Health, Los Angeles, CA, discusses the role of immunotherapy in advanced and recurrent endometrial cancer. She highlights exciting developments in recent trials, particularly the combination of immunotherapy with chemotherapy followed by maintenance PD-1 or PD-L1 inhibition, which has shown improved progression-free survival (PFS) and overall survival (OS) in dMMR (mismatch repair deficient) populations, now considered the standard of care. However, gaps in knowledge remain for the proficient population, emphasizing the importance of further exploration in this area. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
